News AdAlta Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:10:47 2024-05-10 EDT			5-day change	1st Jan Change
0.023 ^AUD	0.00%		-14.81%	-4.17%

04-29	AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	MT
04-08	AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	MT

AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	04-28	MT
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	04-08	MT
AdAlta delivers positive Phase I Extension Study results for AD-214	03-08	AQ
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
AdAlta-La Trobe University Collab Discovers New i-Bodies for Malaria Treatment; Shares Climb 4%	12-18	MT
Adalta Posts Upbeat Results from Phase I Trial of Fibrotic Disease Drug	11-22	MT
AdAlta closes oversubscribed $1.65 million raise	11-08	AQ
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9%	11-07	MT
AdAlta to Seeks AU$1.2 Million from Share Placement	11-03	MT
AdAlta making material progress on partnering talks	23-10-23	AQ
AdAlta Receives AU$2.4 Million R&D Tax Rebate	23-10-18	MT
AdAlta says new AD-214 dosing models enhance partnering potential	23-09-26	AQ
AdAlta completes enrolment for AD-214 fibrosis safety trial	23-09-21	AQ
Adalta Completes Enrollment for Phase 1 Study on Fibrotic Disease Medication; Shares Fall 9%	23-09-20	MT
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
AdAlta to Present at August 24th Virtual Investor Summit	23-08-16	NE
AdAlta back in the clinic with AD-214	23-08-07	AQ
Adalta Carries Out First Dosing in Phase One Extension Study of Fibrotic Disease Medication; Shares Jump 4%	23-08-03	MT
AdAlta eyes AD-214 Phase I extension study	23-07-18	AQ
AdAlta Raises AU$1.9 Million Via Oversubscribed Shortfall Facility	23-07-13	MT

No results for this search